Work

Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.e19038

Authors: Morton Coleman, David Belada, René-Olivier Casasnovas, Rémy Gressin, Hui-Peng Lee, Amitkumar Mehta, Javier Munoz, Gregor Verhoef, Claudia Corrado, Douglas James DeMarini, Wanying Zhao, Xuejun Chen, Keith Fay

Institutions: Cornell University, Weill Cornell Medicine, Charles University, University Hospital Hradec Králové, Inserm, Centre Hospitalier Universitaire de Grenoble, Institut pour l'avancée des biosciences, Université Grenoble Alpes, Flinders Medical Centre, University of Alabama at Birmingham, UAB Medicine, Banner MD Anderson Cancer Center, Universitair Ziekenhuis Leuven, Incyte (United States), Royal North Shore Hospital

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2959327776

Cites:

Cited by: 3

Related to: 10